CytRx to Present at the Sachs Associates Annual Biotech in Europe Investor Forum

• Press Release
• Source: CytRx Corporation
• On 8:30 am EDT, Wednesday September 9, 2009

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR - News) today announced that CytRx President and CEO Steven A. Kriegsman will present a company overview at the Sachs Associates 9^th Annual Biotech in Europe Investor Forum on Monday, September 14, at 2:15 p.m. Central European Summer time. The conference is being held at the SIX Swiss Exchange in Zurich, Switzerland.

Related Quotes

Symbol	Price	Change
CYTR	1.04	-0.01

{"s" : "cytr","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About the Annual Biotech in Europe Investor Forum

The Annual Biotech in Europe Investor Forum is recognized as a leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together a cross-section of companies and an audience of more than 300 investors, analysts and media representatives. The Forum is organized by Sachs Associates, a London-based company that organizes and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 39% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII - News). For more information on the Company, visit www.cytrx.com.

Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com